Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.63
+$0.09 · +1.19%
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Previous close
$7.63
+$0.09 · +1.19%
After-hours
$7.63
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Day range
Current $7.63
52-week range
Current $7.63
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
68
Bullish
Risk
61
High Risk
Momentum
80
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Day range
Current $7.63
52-week range
Current $7.63
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5.09K USD | 19.99K USD | 5.28K USD | 3.73M USD | 166.94K USD |
| Gross profit | −5.09K USD | −19.99K USD | −5.28K USD | −3.73M USD | −166.94K USD |
| Research and development | 18.43M USD | 13.66M USD | 6.65M USD | 3.73M USD | 2M USD |
| Selling, general, and administrative | 7.44M USD | 5.16M USD | 4.57M USD | 4.69M USD | 2.62M USD |
| Operating expenses | 26.46M USD | 19.38M USD | 11.66M USD | 4.69M USD | 4.63M USD |
| Interest income | 1.36M USD | 955.27K USD | 1M USD | 63K USD | 6.26K USD |
| Interest expense | — | — | 133.42K USD | — | 772.8K USD |
| Depreciation and amortization | 4K USD | 13.94K USD | 5.28K USD | 319.71K USD | 162K USD |
| Operating income | −26.46M USD | −19.38M USD | −11.66M USD | −8.43M USD | −6.65M USD |
| Net income | −24.87M USD | −19.58M USD | −11.98M USD | −11.32M USD | −15.51M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$19.67
157.80% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
